NAMSA Experience with NeuroTech Devices

NAMSA Preclinical Experience with NeuroTech Devices

Return to top

NAMSA’s preclinical services provide manufacturers with a comprehensive, globally accessible foundation for evaluating the safety and performance of neurology and neurovascular technologies. Backed by deep therapeutic expertise and GLP‑compliant, AAALAC‑accredited facilities across the US and Europe, our teams design and execute studies that bridge preclinical insights to clinical success—accelerating development while supporting strong, decision‑ready data. To explore our full capabilities and facility resources, visit our Preclinical page.

Preclinical services we offer:

Non-GLP Studies | GLP Studies | Pathology/Histopathology | Bioskills/Physician Training | See All

Preclinical Expertise: NeuroTech Models, Faster Translation, Stronger Submissions

NAMSA supports NeuroTech innovators from concept through clearance by aligning preclinical execution with regulatory strategy from the start. Our consulting teams help:

• To define efficient testing plans
• To support FDA interactions (including pre‑submission planning and responses) and other agencies interactions
• To identify the least‑burdensome path to approval, ensuring preclinical studies generate the right data to support regulatory submissions and first‑in‑human readiness.

Our GLP‑aligned preclinical platform is purpose‑built for central and peripheral neurological devices, combining expertise in neuroanatomy, electrophysiology, biomaterials, and device–tissue interactions. We design studies that capture clinically relevant functional, behavioral, and histopathological endpoints, supporting early feasibility through GLP safety evaluations and producing data packages regulators expect to see.

NAMSA offers broad and flexible NeuroTech‑specific animal models, selecting the most relevant approach for each device and indication, and developing new models with sponsors when none exist. Our experience spans neuromodulation and stimulation, and complex neurovascular and neurosurgical applications such as thrombectomy, embolic devices, aneurysm treatment, dural repair, peripheral nerve repair, neuroma‑reduction, and nerve block systems. These programs are supported across both small and large animal models, including pigs, sheep, dogs, goats, rabbits, and rats.

Why NeuroTech Sponsors Choose NAMSA

• Preclinical strategies designed with the regulatory end goal in mind, not in isolation
• Deep experience across neuromodulation, neurovascular, and neurosurgical technologies
• Ability to avoid common development traps that delay submissions and first‑in‑human studies
• Integrated consulting, preclinical, clinical, and testing expertise for faster, more efficient progression
• More than 50 years of medical device experience and regulator‑recognized reports that build confidence and trust

State of the Art Facilities in the US and Europe

With four strategically located preclinical facilities, two in the United States and two in Europe, NAMSA delivers globally accessible, world‑class environments purpose‑built for neurology device evaluation. Each location is equipped to support a full continuum of preclinical research needs, enabling consistent study execution, rigorous data quality and seamless collaboration across regions. Learn More About our Equipment and Facilities.

Selected Preclinical Projects for NeuroTech Devices

NAMSA brings extensive experience delivering both GLP and non‑GLP preclinical programs for NeuroTech devices, supporting everything from early feasibility and proof‑of‑concept work to pivotal safety and performance studies. Our teams have conducted hundreds of neuro‑focused preclinical projects per year across four global sites, leveraging deep model expertise and decades of in vivo experience to generate high‑quality, decision‑driving data. Whether accelerating early iteration through fast‑paced non‑GLP studies or executing robust GLP programs aligned with regulatory expectations, NAMSA provides the scientific rigor, procedural excellence, and translational insight needed to advance innovative neurotech devices toward clinical readiness.

NAMSA Clinical Experience with NeuroTech Devices

Return to top

NAMSA’s clinical research teams provide end‑to‑end support across every stage of medical device development, from first‑in‑human through pivotal and post‑market studies. Backed by global expertise, rigorous SOPs, and a fully integrated suite of services, we help sponsors generate high‑quality clinical evidence, streamline regulatory submissions, and accelerate time to commercialization. To explore our full clinical capabilities and global support model, visit our Clinical page.

Clinical research services we offer:

Study Design | Trial Management | Data Management | Biostatistics | Medical Writing | See All

NAMSA Expertise with NeuroTech Devices

NAMSA brings deep, hands‑on experience supporting NeuroTech clinical trials. Our teams design studies from the site perspective, accounting for staffing realities, data sources, workflow burden, hospital systems, and patient flow. This practical approach allows us to identify risks early, create protocols sites can realistically execute, and help sponsors avoid delays, reduce friction, and save time throughout the clinical process.

Our operational insight is shaped by SMEs with direct experience working alongside patients, surgeons, cath‑lab teams, and neurology specialists. This enables us to anticipate how neuro‑specific protocols perform in real clinical environments, where data gaps may occur, and how to design collection strategies that ensure consistent, high‑quality data. Combined with physician‑led clinical strategy, neuro‑specialized data management and biostatistics, safety oversight, imaging core lab capabilities, and access to Key Opinion Leaders, we deliver a comprehensive approach that supports smoother enrollment and faster progress toward regulatory and commercial milestones.

How NAMSA Improves Execution and Outcomes

• Designs protocols grounded in real‑world site operations, reducing burden on coordinators and clinical staff
• Anticipates enrollment and data‑collection challenges before they impact timelines
• Understands true patient pathways, from outpatient neurology clinics to emergency, stroke, surgical, and referral‑based care
• Aligns clinical execution with regulatory and commercial goals from the outset
  Improves data completeness, consistency, and readiness for submission

Neurology and neurosurgical experience spans:

• Neurodegenerative and movement disorders such as Parkinson’s disease and ALS
• High‑acuity neurovascular and stroke interventions
• Aneurysm treatment, embolization, coiling, stenting, liquid embolics, and flow diversion
• Advanced spinal and minimally invasive neurosurgical procedures
• Adjacent neurologic conditions including Multiple Sclerosis, Huntington’s disease, and Tardive Dyskinesia
• Early‑phase regenerative approaches such as stem‑cell‑based therapies

Together, this experience allows NAMSA to deliver neuro clinical programs that are practical to run, trusted by regulators, and designed to move your technology forward with confidence and speed.

Selected Clinical Research Projects for NeuroTech Devices

NAMSA has extensive experience managing a wide range of clinical projects for NeuroTech devices, spanning neuromodulation, neurovascular, neurosurgical, and neurological monitoring technologies. Our global clinical teams provide flexible support models, whether sponsors need targeted, a‑la‑carte services like monitoring, biostatistics, data management, imaging core lab, CEC/DSMB oversight, or fully comprehensive, end‑to‑end clinical trial execution. This depth of expertise has enabled NAMSA to support dozens of NeuroTech clinical studies across multiple geographies and study types, including first‑in‑human, pivotal, PMCF, and post‑market projects. To learn more about how our clinical outsourcing models can accelerate your program, visit our outsourcing and Functional Service Provider page.

NAMSA Experience Testing NeuroTech Devices

Return to top

NAMSA is the pioneer of the medical device testing industry and continues to serve as the global leader for reliable medical device testing services. We have developed a reputation for excellence in biocompatibility, analytical chemistry, microbiology, and sterility testing, an every year more than 3,000 medical device and IVD companies trust us to ensure the safety and compliance of their devices.

Testing services we offer:

Biocompatibility Testing | Microbiological Testing | Sterility Testing | See All

Types of Tests We Conduct on NeuroTech Devices

For NeuroTech devices, especially implantable, long‑term, or electrically active systems, NAMSA delivers integrated safety aligned with the unique risks of neurological environments.

• Biocompatibility evaluations ensure materials used in neural interfaces, stimulators, shunts, and neurovascular implants meet ISO 10993 requirements while accounting for neurological tissue sensitivity.
• Chemical characterization programs define material composition, identify extractables and leachables, and support long‑term material safety for devices intended for extended in‑vivo use.
• Microbiology services address contamination risk through tailored bioburden and endotoxin strategies designed for complex neuro device geometries.
• Sterility expertise supports robust sterilization validation approaches aligned with neuromodulation and neurovascular implant pathways.

Together, these capabilities provide a neurology‑focused testing strategy that reduces risk, supports regulatory expectations, and accelerates progress toward clinical use.

Compliance and Consulting Experience With NeuroTech Devices

Return to top

From biological safety plans to FDA strategy and support, NAMSA has deep expertise in medical device compliance. Our extensive team of QA/RA and biological safety consultants, medical writers, scientists and market research experts all have first-hand experience with medical device industry manufacturers. They understand how to balance the benefit-risk ratio with the practicalities of regulatory compliance. Because NAMSA performs preclinical studies, clinical research and testing on thousands of medical devices and IVDs each year, our consultants come to each project with a well-informed sense of what the US FDA, European Notified Bodies and other national regulators expect.

Selected compliance services we offer:

US FDA Compliance |  EU MDR/IVDR Compliance | Biological Safety Consulting | Global Compliance | See All

Premarket Strategy to Postmarket Support

NAMSA’s compliance services are designed to guide manufacturers through the full spectrum of global regulatory requirements, with a strong emphasis on submission strategy and readiness. Our regulatory experts, including former FDA and EU Notified Body staff, help clients develop clear, efficient pathways for 510(k), PMA, De Novo, IDE, MDR/IVDR, and international submissions, ensuring documentation, clinical evidence, and risk management plans align with regulator expectations. From early strategic planning through post‑market support, we provide the insight, structure, and cross‑functional alignment needed to navigate complex compliance landscapes and achieve timely, confident market entry.